BRBR
BellRing Brands, Inc. · Saint Louis, MO · IPO 2019
$18.15
All-time High $80.67  ·  Down 77% from peak
M/Cap $2.149B
P/E 12.46 · Ind. 18.25
FY End Sep 30
Brands Premier Protein · Dymatize
IPO CAGR 18%
FY2026 Guide +4% to +8%
Verdict
BellRing's 18% CAGR since IPO was real — but the last two years were partly retailer stockpiling, not organic demand. That channel is destocking, core shakes revenue just went negative, a class action has been filed, and the long-term growth algorithm has been cut. The business is not broken — ROIC #2 of 64 peers, 25% RTD market share, genuine GLP-1 tailwind. But at Fwd P/E 8.32 the market is already pricing serious pain. Show-me story. Two clean quarters of consumer pull is the buy trigger.
Business Quality Score
RG
3
GM
3
OC
3
OM
3
NI
3
FCF
3
18 / 30  ·  All categories max-scored
Analyst Consensus · 15 Analysts
$23
Low
$31.43
Avg
$40
High
Current $18.15 — 21% below lowest analyst target of $23
11
Buy / Outperform
4
Hold / Underperform
Earnings Surprise History
−Q1
+Q2
−Q3
++Q4
RG Est  +4.34% FY2026  ·  +5.97% FY2027
Net Sales Growth — hover bars for detail
Net Sales ($M)
YoY Growth %
Revenue Breakdown — hover rows for detail
SegmentFY2024 MixYoYFY2025 MixYoYQ1 FY2026 MixYoY
Total Revenue$1,996M+20%$2,313M+16%—+1%
Shakes & Beverages81%+22%82%+17%81%−2%
Powders16%+13%16%+12%17%+13%
Other3%—2%−14%2%+5%
⚠ Shakes — 81% of revenue — flipped to −2% in Q1 FY2026. Powders (+13%) are too small to offset. The destocking is hitting the core engine directly.
Margin Compression
Gross Margin
35.4% FY2433.2% FY2530.0% Q1'26
Operating Margin
19.4% FY2415.4% FY2514.5% Q1'26
FY2024
FY2025
Q1 FY2026
Gross margin down 540bps in 18 months. Planned ad spend increase (4–5% of sales) adds further near-term headwind.
Valuation vs. 64 Peers — hover to highlight
P/E
12.46
#12 / 64
Fwd P/E
8.32
#7 / 64
P/FCF
8.62
#10 / 64
P/S
0.92
#36 / 64
PEG
2.39
#16 / 64
ROIC
27.16%
#2 / 64
ROA
18.81%
#1 / 64
Dividend
None
—
Key Events & Catalysts — click any row to expand
LawsuitSecurities class action filed Feb 25, 2026
▼
Alleges BellRing's strong reported sales masked reality — results were materially attributable to temporary inventory stockpiling by key customers, not genuine end-consumer demand. CFO framed destocking as a "one-time event." Legal uncertainty, settlement costs, and management distraction are real and unquantifiable.
Algorithm CutLong-term growth target revised down — Nov 2025
▼
Management cut the long-term net sales CAGR target from 10–12% to 7–9%, and EBITDA margins to 18–20%. FY2026 guidance set at $2.41–$2.49B net sales (+4–8%), EBITDA $425–$455M. Q1 guided soft; recovery loaded into H2. Stock dropped 31% in premarket after Q3 FY2025 despite beating estimates — the market had already lost confidence.
Share LossPremier Protein RTD share: 30% → 25% in 6 months
▼
Premier Protein reached a new RTD category high of 30% in March 2025 — the peak. By Q3 FY2025, share had declined to 25%. A 500bps drop in under 6 months is significant for a brand that was seen as the dominant category leader. Still #1, but the direction is wrong.
Concentration3 customers = 74.8% of total revenue
▼
Walmart (incl. Sam's Club), Costco, and Amazon = 74.8% of BellRing's total revenue. Any delistings, shelf-space reductions, or pricing disputes at these three accounts would be devastating. No meaningful channel diversification exists.
Pattern RiskFY2022 cash flow collapse — this has happened before
▼
FY2022 operating cash flow collapsed from $226M to $21M — entirely due to retailer inventory build ahead of supply constraints. The same channel distortion is now playing out in reverse. This is a structural feature of BellRing's go-to-market model, not a one-time anomaly.
GLP-1 TailwindProtein demand structurally rising with GLP-1 adoption
▼
Management positioning protein as complementary to GLP-1 drug adoption. As Wegovy and Ozempic become affordable and mainstream, preserving muscle mass during weight loss becomes a consumer priority. Premier Protein — cheap, accessible, already in Walmart/Costco — is well-placed to benefit if the narrative lands at scale.
Track RecordNet sales doubled FY2020–FY2024 — 18% IPO CAGR
▼
Net sales grew from $988M (FY2020) to $1,996M (FY2024) — 18% CAGR since IPO, well ahead of the original 10–12% target. Adjusted EBITDA grew from $197M to $440M. The compound engine is real. The question is how much of the recent growth was genuine versus channel-inflated.
Key Risks
Destocking Deeper Than GuidedQ1 FY2026 shakes already went negative (−2%). If destocking continues into Q2–Q3, the revenue reset is materially worse than +4–8% implies.
Securities Lawsuit OverhangClass action filed Feb 2026. Settlement costs and management distraction are real and unquantifiable.
Structural Margin PressureGross margin down 540bps over 18 months. Planned ad spend increase adds further near-term headwind.
Customer Concentration3 customers = 74.8% of revenue. No pricing power. Revenue that can reverse faster than it built.
Upside Catalysts
Genuine Demand RecoveryIf Q2/Q3 FY2026 show organic consumer pull — not channel refill — the destocking narrative ends and earnings reaccelerate. The single most important thing to watch.
GLP-1 Protein TailwindAs semaglutide and tirzepatide go mainstream, dietary protein demand structurally rises. Premier Protein is cheap, accessible, already in Walmart/Costco.
Dymatize International GrowthPowders holding +12–13% consistently. Dymatize has international reach and a distinct fitness-science identity — underpenetrated vs. Premier Protein.
Valuation Floor Is CompellingFwd P/E 8.32 (#7/64), P/FCF 8.62 (#10/64). ROA #1 and ROIC #2 in peer group. Stabilisation could drive a sharp re-rate.
Conviction Level
WAIT
Needs 2 clean quarters first
Bull vs. Bear
BULL
  • ✓ Destocking is genuinely one-time
  • ✓ GLP-1 drives structural protein demand
  • ✓ Dymatize international accelerates
  • ✓ Fwd P/E 8.32 = extreme value floor
  • ✓ Lawsuit settles without major damage
BEAR
  • ✗ Destocking continues 2–3 more quarters
  • ✗ RTD market share keeps sliding from 25%
  • ✗ Lawsuit disrupts management execution
  • ✗ 3-customer concentration creates fragility
  • ✗ Margin compression becomes structural
What to Watch
Key Catalyst Date
Q2 FY2026 Earnings — ~May 2026
First real test of whether consumer pull is recovering organically
SIGNAL 1
Shakes YoY growth
turns positive
SIGNAL 2
Gross margin
stabilises above 31%
SIGNAL 3
Management confirms
retailers no longer destocking
Bottom Line

BellRing's revenue growth story over the past two years was partly real, partly manufactured by channel behaviour. Premier Protein is a legitimate category leader — still at 25% RTD market share — but that share is sliding, and the "demand" that drove FY2024's 20% growth included meaningful retailer inventory hoarding that is now being reversed. Management acknowledged it too late, the class action is filed, and growth targets have been cut.

The bull case is straightforward: (1) destocking completes by H2 FY2026, (2) GLP-1 mainstreaming becomes a real incremental driver for protein consumption, and (3) Dymatize continues its international trajectory. At Fwd P/E 8.32 with ROIC #2 among 64 peers, you are not paying for growth — you are paying for stabilisation.

Not a short-term trade. Watch the Q2 FY2026 report (~May 2026) closely. Two clean quarters of genuine sell-through data is the buy trigger. Until then, cheap valuation and broken management credibility cancel each other out.